The effects of resveratrol on osteosarcoma cells: Regulation of the interaction between JAK2/STAT3 signaling pathway and tumor immune microenvironment.
- Author:
Xiaoli WANG
1
;
Guoliang MA
1
;
Ruidong LIU
1
;
Ruixia QI
1
;
Jiudei QI
2
;
Yuguo REN
3
,
4
Author Information
1. Laboratory Department, Jinan People's Hospital, Jinan 271199, China.
2. Department of Oncology, Jinan People's Hospital, Jinan 271199, China.
3. Laboratory Department, Jinan People's Hospital, Jinan 271199, China. *Corresponding author, E-mail: Jnrenyuguo@
4. com.
- Publication Type:Journal Article
- MeSH:
Osteosarcoma/genetics*;
STAT3 Transcription Factor/genetics*;
Resveratrol/pharmacology*;
Animals;
Janus Kinase 2/genetics*;
Signal Transduction/drug effects*;
Tumor Microenvironment/immunology*;
Cell Line, Tumor;
Mice, Inbred C57BL;
Mice;
Humans;
Cell Proliferation/drug effects*;
Bone Neoplasms/metabolism*;
CD8-Positive T-Lymphocytes/drug effects*;
Xenograft Model Antitumor Assays
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(5):420-427
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of resveratrol on the tumor microenvironment in osteosarcoma. Methods A C57BL/6 xenograft mouse model was established and treated with resveratrol. Single-cell sequencing was performed to analyze changes in the tumor microenvironment. Immunohistochemistry was used to assess immune cell infiltration, while Western blotting was conducted to examine alterations in cellular signaling pathways. Results Resveratrol significantly inhibited the proliferation of LM8 osteosarcoma cells in C57BL/6 mice compared to the control group. Additionally, CD8+ T cell recruitment was enhanced. The Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway was notably downregulated in LM8 osteosarcoma cells following resveratrol treatment. Conclusion Resveratrol promotes CD8+ T cell infiltration by inhibiting the JAK2/STAT3 signaling pathway, suggesting its potential as a therapeutic agent in osteosarcoma treatment.
